Solence, based in Paris, is addressing a gap in women’s health care by focusing on Polycystic Ovary Syndrome (PCOS), a widespread yet underrecognized condition. The company recently secured €1.6M in seed funding to continue its work on digital solutions that assist women in managing PCOS. This funding round saw participation from various investors, including Impact Shakers Ventures and notable figures like Céline Lazorthes and Stephane Mardel. The founder, Clara Stephenson, combines personal experience with a professional background to pioneer support for women affect by this condition.
Large-scale studies reveal that a significant portion of women with PCOS do not receive adequate care, leading to various health complications. Solence’s approach using digital mechanisms to address these needs aligns with historical trends emphasizing non-medical interventions for better management. Previous efforts often leaned heavily on medication, but more recent guidelines advocate for holistic lifestyle and behavioral changes as initial interventions.
What Sets Solence Apart?
Solence emerges as a platform founded in 2022 with the clear goal of supporting women with PCOS through innovative tools. These tools focus on lifestyle management, supported by artificial intelligence, to improve accessibility and mitigate the long-term impact of PCOS. This digital health solution is aimed at integrating symptom management into daily life effectively.
How Does Solence Plan to Execute Its Mission?
The company offers a twelve-week digital program designed for comprehensive care for PCOS, rooted in peer-reviewed research. This program involves interactive learning to encourage symptom reversal alongside personalized assessments. The program embraces data insights to tailor care to each user’s unique needs, moving beyond traditional pharmaceutical solutions. Solence’s advisory list includes experts like Professor Michel Pugeat, reinforcing its scientific backing.
PCOS affects nearly 20% of women globally, yet 85% reportedly lack sufficient support. Symptoms vary greatly, from physical manifestations like weight gain to mental health issues. The company aims to fill these service gaps where medication predominates, despite the presence of guidelines advocating for more natural approaches.
“The general public needs information on PCOS… management by all health professionals… innovative therapeutic approaches, such as that of Solence,” stated Professor Pugeat.
An initial focus for Solence involves expanding its patient application, intended to offer support through personalized lifestyle guidance. The recent funding will facilitate further enhancements to this app, reinforcing clinical partnerships and expanding the reach of its distribution channels. This intent demonstrates the use of innovative approaches that strive to enhance women’s quality of life.
“PCOS is one of the great blind spots in women’s healthcare… Our vision is to leverage data… improving their healthy life expectancy,” remarked Clara Stephenson.
The support from investors, including Impact Shakers Ventures, emphasizes confidence in the potential impact of Solence on women’s health. The platform seeks not only to address immediate health challenges but also engage in long-term preventive care strategies that could reach a broader community globally. Solence’s nuanced strategy displays an understanding of unmet needs, aiming to deliver meaningful, scalable health solutions through revolutionary care models.
